Back to top
more

Adamis Pharmaceuticals Corporation (ADMP)

(Delayed Data from NSDQ)

$2.07 USD

2.07
236,541

0.00 (0.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.08 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Adamis (ADMP) a New Buy Stock

by Zacks Equity Research

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sanghamitra Saha headshot

5 Winning Stocks to Land on the Overlooked Rising P/E Trick

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -8.70% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

by Zacks Equity Research

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

New Strong Sell Stocks for June 15th

by Zacks Equity Research

CTRN, SI, ADMP, ISBA, and DGICA have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2021

Will Adamis Pharmaceuticals (ADMP) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar

by Zacks Equity Research

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% Higher

by Zacks Equity Research

Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS

by Zacks Equity Research

Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.

Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for September 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.

Adamis (ADMP) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adamis (ADMP) delivered earnings and revenue surprises of -83.33% and -9.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.